Introduction

When a district court opts to administratively close rather than formally stay a patent infringement case, it signals something strategically significant: PTAB proceedings may reshape the battlefield entirely before litigation resumes. That is precisely the situation in Capsa Solutions, LLC v. Howard Industries, Inc., Case No. 2:22-cv-00065, before the U.S. District Court for the Southern District of Mississippi.

Filed in May 2022, this medical cart patent infringement dispute involves seven patents covering mobile workstation technology — from tilting keyboard trays to full telemedicine cart systems. Howard Industries, the defendant, successfully initiated inter partes review (IPR) proceedings at the USPTO’s Patent Trial and Appeal Board (PTAB) targeting two of the most contested patents. The district court’s April 2024 administrative closure, unopposed by Capsa Solutions, effectively places the litigation in standby mode. For patent attorneys, IP professionals, and R&D teams operating in the healthcare technology space, this case offers a textbook example of coordinated parallel PTAB-district court defense strategy.

Case Overview

The Parties

The Patents at Issue

This litigation involves seven patents covering mobile workstation technology critical to the healthcare sector, from mechanical cart designs to specific user interface elements. These patents collectively protect the functional and aesthetic architecture of Capsa’s mobile healthcare workstation technology.

• • US7,594,668B2 — Mechanical cart design (Targeted by IPR2023-01274)
• • US8,109,527B2 — Cart structural components
• • US8,215,650B2 — Cart tilt and slide mechanisms (Targeted by IPR2023-01275)
• • US9,039,016B2 — Workstation assembly
• • US10,159,337B2 — Mobile workstation configuration
• • US10,299,582B2 — Cart platform systems
• • USD762,339S — Ornamental design patent

Litigation Timeline & Procedural History

• May 12, 2022: Capsa Solutions files its patent infringement complaint in the Southern District of Mississippi.
• 2022–2023: Case proceeds through initial pleadings, discovery, and motion practice. Howard Industries assembles a large defense team, signaling a serious defense posture.
• 2023: Howard Industries files two IPR petitions at PTAB: IPR2023-01274 and IPR2023-01275, targeting US7,594,668B2 and US8,215,650B2 respectively.
• Early 2024: Howard files a Motion to Stay pending IPR final written decisions. Capsa Solutions files a non-opposition response.
• April 2, 2024: Chief Judge Ozerden administratively closes the case, denying the stay motion as moot. The court retains jurisdiction, with a reopening deadline set at 30 days following PTAB’s final written decisions.

The approximately two-year duration before administrative closure reflects the complexity of multi-patent healthcare technology litigation and the strategic sequencing Howard Industries employed to shift the validity fight to PTAB.

The Verdict & Legal Analysis

Outcome

This case is not concluded. The April 2, 2024 order administratively closes the case for statistical purposes only — a procedural mechanism distinct from a stay or dismissal. Chief Judge Ozerden explicitly preserved the court’s jurisdiction and established a clear reopening pathway tied to PTAB’s final written decisions in IPR2023-01274 and IPR2023-01275. No damages have been awarded. No injunctive relief has been granted or denied. The substantive merits remain fully open.

Verdict Cause Analysis: The PTAB Strategy

Howard Industries’ decision to petition for IPR on two of the seven asserted patents — and then move to stay district court proceedings — is a well-established and increasingly common defense strategy in patent litigation. By challenging validity at PTAB, Howard sought several tactical advantages:

• Estoppel Management: A final written decision from PTAB creates estoppel limitations on invalidity arguments that can be raised later in district court — but a successful IPR can also cancel claims entirely, mooting infringement allegations.
• Cost Efficiency: PTAB proceedings are generally faster and less expensive than district court validity trials. Invalidating even two of seven asserted patents narrows Capsa’s damages exposure and litigation leverage.
• Claim Construction Influence: PTAB’s claim construction analysis, even under the Phillips standard now applied post-SAS Institute, can inform how the district court approaches construction of related claims across the remaining five patents.

Notably, Capsa Solutions did not oppose the stay motion — a strategic decision that avoids the costs of parallel proceedings while preserving its full infringement case for resumption after PTAB resolves the validity questions.

Legal Significance

The administrative closure mechanism, rather than a formal stay, reflects judicial efficiency preferences. Courts increasingly use administrative closure to manage docket statistics while preserving the flexibility to reopen without formal reinstatement procedures. For practitioners, this distinction matters: reopening timelines are court-ordered (30 days post-PTAB decision), providing litigation schedule certainty.